prednisone has been researched along with Muscle Contraction in 31 studies
Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.
Muscle Contraction: A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To review the experience with high-dose intravenous pulse methylprednisolone (IVMP) therapy in patients with juvenile dermatomyositis (JDM) in our institution." | 7.69 | Failure of pulse intravenous methylprednisolone treatment in juvenile dermatomyositis. ( Dooley, J; Lang, B, 1996) |
| "In patients with myasthenia gravis who received single doses of prednisone orally (40 to 100 mg), we found acute inhibition of neuromuscular function as manifest by increased decremental responses to repetitive nerve stimulation, reduced twitch tension, and lowered maximum voluntary contraction strength." | 7.67 | Prednisone-induced worsening of neuromuscular function in myasthenia gravis. ( Miller, RG; Milner-Brown, HS; Mirka, A, 1986) |
| " The results suggest that (i) DFC and PRED in equal anti-inflammatory dosage are similarly or equally efficient in slowing down the decline of muscle strength in DMD; (ii) benefits outweigh the side effects." | 6.68 | Deflazacort vs. prednisone in Duchenne muscular dystrophy: trends of an ongoing study. ( Reitter, B, 1995) |
| "To review the experience with high-dose intravenous pulse methylprednisolone (IVMP) therapy in patients with juvenile dermatomyositis (JDM) in our institution." | 3.69 | Failure of pulse intravenous methylprednisolone treatment in juvenile dermatomyositis. ( Dooley, J; Lang, B, 1996) |
| "In patients with myasthenia gravis who received single doses of prednisone orally (40 to 100 mg), we found acute inhibition of neuromuscular function as manifest by increased decremental responses to repetitive nerve stimulation, reduced twitch tension, and lowered maximum voluntary contraction strength." | 3.67 | Prednisone-induced worsening of neuromuscular function in myasthenia gravis. ( Miller, RG; Milner-Brown, HS; Mirka, A, 1986) |
| " The present study was designed to evaluate the ability of specific inspiratory muscle training (SIMT) to prevent the effects of a therapeutic dosage of corticosteroids on inspiratory muscle function in patients receiving the drug for diseases other than pulmonary, with no underlying respiratory or muscular disease." | 2.68 | Inspiratory muscle training during treatment with corticosteroids in humans. ( Azgad, Y; Weiner, M; Weiner, P, 1995) |
| " The results suggest that (i) DFC and PRED in equal anti-inflammatory dosage are similarly or equally efficient in slowing down the decline of muscle strength in DMD; (ii) benefits outweigh the side effects." | 2.68 | Deflazacort vs. prednisone in Duchenne muscular dystrophy: trends of an ongoing study. ( Reitter, B, 1995) |
| " Both disease remission and a reduction in corticosteroid dosage were obtained in four patients." | 2.38 | Treatment of idiopathic inflammatory myopathies with cyclophosphamide pulses: clinical experience and a review of the literature. ( De Vita, S; Fossaluzza, V, 1992) |
| " Gradual steroid dosage tapering resulted in marked improvement in both strength and endurance; the inspiratory muscle strength rose significantly to 112." | 1.29 | The effect of corticosteroids on inspiratory muscle performance in humans. ( Azgad, Y; Weiner, M; Weiner, P, 1993) |
| " Serial MEVs were not only useful for prognosis, but also helpful in regulating the dosage of prednisone." | 1.26 | Prognostic value of minimal excitability of facial nerve in Bell's palsy. ( Challenor, Y; Devi, S; Duarte, N; Lovelace, RE, 1978) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (45.16) | 18.7374 |
| 1990's | 11 (35.48) | 18.2507 |
| 2000's | 6 (19.35) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Painter, PL | 1 |
| Topp, KS | 1 |
| Krasnoff, JB | 1 |
| Adey, D | 1 |
| Strasner, A | 1 |
| Tomlanovich, S | 1 |
| Stock, P | 1 |
| Crawford, BA | 1 |
| Liu, PY | 1 |
| Kean, MT | 1 |
| Bleasel, JF | 1 |
| Handelsman, DJ | 1 |
| Campbell, C | 1 |
| Jacob, P | 1 |
| Ashok Muley, S | 1 |
| Day, JW | 1 |
| Greenberg, SA | 1 |
| Restrepo, S | 1 |
| Resnick, JS | 1 |
| Mammel, M | 1 |
| Mundale, MO | 1 |
| Kottke, FJ | 1 |
| Weiner, P | 2 |
| Azgad, Y | 2 |
| Weiner, M | 2 |
| King, LE | 1 |
| Park, JH | 1 |
| Adams, LB | 1 |
| Olsen, NJ | 1 |
| Fafalak, RG | 1 |
| Peterson, MG | 1 |
| Kagen, LJ | 1 |
| Fernandez-Sola, J | 1 |
| Cusso, R | 1 |
| Picado, C | 1 |
| Vernet, M | 1 |
| Grau, JM | 1 |
| Urbano-Marquez, A | 1 |
| Voll, C | 1 |
| Ang, LC | 1 |
| Sibley, J | 1 |
| Card, R | 1 |
| Lefevre, K | 1 |
| Lang, B | 1 |
| Dooley, J | 1 |
| Reitter, B | 1 |
| Badr, AS | 1 |
| Saadeh, CK | 1 |
| Yeary, J | 1 |
| Hamous, J | 1 |
| Khandheria, B | 1 |
| Vasilescu, C | 1 |
| Bucur, G | 1 |
| Petrovici, A | 1 |
| Florescu, A | 1 |
| Winkler, LH | 1 |
| Winkler, GF | 1 |
| Devi, S | 1 |
| Challenor, Y | 1 |
| Duarte, N | 1 |
| Lovelace, RE | 1 |
| Sieb, JP | 1 |
| Dengler, R | 1 |
| Jerusalem, F | 1 |
| De Vita, S | 1 |
| Fossaluzza, V | 1 |
| Fillyaw, MJ | 1 |
| Tandan, R | 1 |
| Bradley, WG | 1 |
| Miller, RG | 1 |
| Milner-Brown, HS | 1 |
| Mirka, A | 1 |
| Danneskiold-Samsøe, B | 3 |
| Grimby, G | 3 |
| Horber, FF | 1 |
| Scheidegger, JR | 1 |
| Grünig, BE | 1 |
| Frey, FJ | 1 |
| Sultan, IH | 1 |
| Patten, BM | 1 |
| Oliver, KL | 1 |
| Engel, WK | 1 |
| Walsh, JC | 1 |
| Cuddigan, JH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Duchenne Muscular Dystrophy: Double-blind Randomized Trial to Find Optimum Steroid Regimen[NCT01603407] | Phase 3 | 196 participants (Actual) | Interventional | 2013-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Measures the total distance walked in 6 minutes averaged over all post-baseline follow-up visits through Month 36. (NCT01603407)
Timeframe: Average of Months 3, 6, 12, 18, 24, 30 and 36 visits
| Intervention | meters (Least Squares Mean) |
|---|---|
| Daily Prednisone | 384.95 |
| Daily Deflazacort | 384.17 |
| Intermittent Prednisone | 346.81 |
Forced vital capacity was measured during a spirometry test. Forced expiratory volume (FEV) measures how much air a person can exhale during a forced breath. Forced vital capacity (FVC) is the total amount of air exhaled during the FEV test. (NCT01603407)
Timeframe: Average of Months 3, 6, 12, 18, 24, 30 and 36 visits
| Intervention | liters (Least Squares Mean) |
|---|---|
| Daily Prednisone | 1.4 |
| Daily Deflazacort | 1.4 |
| Intermittent Prednisone | 1.5 |
Measured by trans-thoracic echocardiogram and 12-lead ECG. (NCT01603407)
Timeframe: 36 months
| Intervention | percentage of fractional shortening (Least Squares Mean) |
|---|---|
| Daily Prednisone | 33.74 |
| Daily Deflazacort | 34.01 |
| Intermittent Prednisone | 34.33 |
Measured by trans-thoracic echocardiogram and 12-lead ECG. (NCT01603407)
Timeframe: 36 months
| Intervention | bpm (Least Squares Mean) |
|---|---|
| Daily Prednisone | 94.10 |
| Daily Deflazacort | 93.52 |
| Intermittent Prednisone | 91.65 |
Measured by trans-thoracic echocardiogram and 12-lead ECG. (NCT01603407)
Timeframe: 36 months
| Intervention | percentage of ejection fraction (Least Squares Mean) |
|---|---|
| Daily Prednisone | 61.88 |
| Daily Deflazacort | 62.65 |
| Intermittent Prednisone | 62.45 |
"The North Star Ambulatory Assessment (NSAA) is a 17-item rating scale that is used to measure functional motor abilities in ambulant children with Duchenne Muscular Dystrophy (DMD). It is usually used to monitor the progression of the disease and treatment effects.~The activities are graded as follows:~2 - Normal - no obvious modification of activity~1 - Modified method but achieves goal independent of physical assistance from another 0 - Unable to achieve independently This scale is ordinal with 34 as the maximum score indicating fully-independent function." (NCT01603407)
Timeframe: Average of Months 3, 6, 12, 18, 24, 30 and 36 visits
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Daily Prednisone | 23.7 |
| Daily Deflazacort | 24.0 |
| Intermittent Prednisone | 20.7 |
The number of participants who completed 36 months of follow-up on the originally assigned dosage (for weight) of study medication. (NCT01603407)
Timeframe: 3 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Daily Prednisone | 36 |
| Daily Deflazacort | 36 |
| Intermittent Prednisone | 37 |
(NCT01603407)
Timeframe: 36 months
| Intervention | kilograms/square meter (Least Squares Mean) |
|---|---|
| Daily Prednisone | 18.9 |
| Daily Deflazacort | 18.3 |
| Intermittent Prednisone | 18.1 |
(NCT01603407)
Timeframe: 36 months
| Intervention | centimeters (Least Squares Mean) |
|---|---|
| Daily Prednisone | 116.8 |
| Daily Deflazacort | 115.3 |
| Intermittent Prednisone | 119.9 |
(NCT01603407)
Timeframe: 36 months
| Intervention | kilograms (Least Squares Mean) |
|---|---|
| Daily Prednisone | 26.3 |
| Daily Deflazacort | 24.9 |
| Intermittent Prednisone | 26.3 |
Measured by trans-thoracic echocardiogram and 12-lead ECG. (NCT01603407)
Timeframe: 36 months
| Intervention | milliseconds (Least Squares Mean) |
|---|---|
| Daily Prednisone | 115.59 |
| Daily Deflazacort | 116.87 |
| Intermittent Prednisone | 117.90 |
Quality of life was measured by parent/guardian self-report for all children utilizing the PEDSQL measurement tool. This is a 23-question tool. Scores can range from 0 to 100, with higher scores indicating better quality of life for the child. (NCT01603407)
Timeframe: Average of Months 12, 24, and 36 visits
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Daily Prednisone | 64.88 |
| Daily Deflazacort | 63.71 |
| Intermittent Prednisone | 61.33 |
Quality of life was measured by child self-report in children age 5 and older utilizing the PEDSQL measurement tool. This is a 23-question tool. Scores can range from 0 to 100, with higher scores indicating better quality of life. (NCT01603407)
Timeframe: Average of Months 12, 24, and 36 visits
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Daily Prednisone | 67.39 |
| Daily Deflazacort | 64.96 |
| Intermittent Prednisone | 65.07 |
Range of motion at the ankle joint in dorsiflexion measured in degrees from plantigrade averaged over all post-baseline visits. (NCT01603407)
Timeframe: Average of Months 3, 6, 12, 18, 24, 30 and 36 visits
| Intervention | degrees (Mean) |
|---|---|
| Daily Prednisone | 4.39 |
| Daily Deflazacort | 3.29 |
| Intermittent Prednisone | 2.67 |
Range of motion at the ankle joint in dorsiflexion measured in degrees from plantigrade averaged over all post-baseline visits. (NCT01603407)
Timeframe: Average of Months 3, 6, 12, 18, 24, 30 and 36 visits
| Intervention | degrees (Mean) |
|---|---|
| Daily Prednisone | 4.05 |
| Daily Deflazacort | 2.81 |
| Intermittent Prednisone | 2.29 |
Reciprocal of time to rise from the floor (NCT01603407)
Timeframe: Average of Months 3, 6, 12, 18, 24, 30 and 36 visits
| Intervention | rise/sec (Least Squares Mean) |
|---|---|
| Daily Prednisone | 0.24 |
| Daily Deflazacort | 0.24 |
| Intermittent Prednisone | 0.18 |
The TSQM Global Satisfaction with Treatment is a 14-item questionnaire that ranges from 0 - 100 with higher scores indicating better outcomes. (NCT01603407)
Timeframe: Average of Months 3, 6, 12, 18, 24, 30 and 36 visits
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Daily Prednisone | 71.2 |
| Daily Deflazacort | 67.8 |
| Intermittent Prednisone | 65.1 |
2 reviews available for prednisone and Muscle Contraction
| Article | Year |
|---|---|
Deflazacort for the treatment of Duchenne Dystrophy: a systematic review.
Topics: Adolescent; Anti-Inflammatory Agents; Child; Child, Preschool; Humans; Immunosuppressive Agents; Mal | 2003 |
Treatment of idiopathic inflammatory myopathies with cyclophosphamide pulses: clinical experience and a review of the literature.
Topics: Aged; Creatine Kinase; Cyclophosphamide; Dose-Response Relationship, Drug; Female; Humans; Injection | 1992 |
4 trials available for prednisone and Muscle Contraction
| Article | Year |
|---|---|
Health-related fitness and quality of life following steroid withdrawal in renal transplant recipients.
Topics: Adult; Anti-Inflammatory Agents; Body Composition; Female; Graft Rejection; Heart Rate; Humans; Kidn | 2003 |
Randomized placebo-controlled trial of androgen effects on muscle and bone in men requiring long-term systemic glucocorticoid treatment.
Topics: Anabolic Agents; Bone Density; Drug Interactions; Glucocorticoids; Gonadal Steroid Hormones; Humans; | 2003 |
Inspiratory muscle training during treatment with corticosteroids in humans.
Topics: Adrenal Cortex Hormones; Adult; Airway Resistance; Female; Forced Expiratory Volume; Glomerulonephri | 1995 |
Deflazacort vs. prednisone in Duchenne muscular dystrophy: trends of an ongoing study.
Topics: Alkaline Phosphatase; Anti-Inflammatory Agents; Body Weight; Child; Child, Preschool; Creatine Kinas | 1995 |
25 other studies available for prednisone and Muscle Contraction
| Article | Year |
|---|---|
Autoimmune rippling muscle.
Topics: Anemia, Hemolytic, Autoimmune; Autoantibodies; Electromyography; Humans; Immunosuppressive Agents; M | 2003 |
Acquired rippling muscle disease with myasthenia gravis.
Topics: Adult; Alopecia Areata; Antineoplastic Agents; Electromyography; Humans; Male; Muscle Contraction; M | 2004 |
New treatment alternatives for Duchenne and Becker muscular dystrophy.
Topics: Administration, Oral; Adrenergic beta-Agonists; Albuterol; Child; Child, Preschool; Clinical Trials | 2004 |
Muscular strength as an index of response to therapy in childhood dermatomyositis.
Topics: Adolescent; Azathioprine; Biomechanical Phenomena; Child; Child, Preschool; Creatine Kinase; Dermato | 1981 |
Phosphorus 31 magnetic resonance spectroscopy for quantitative evaluation of therapeutic regimens in dermatomyositis.
Topics: Adenosine Triphosphate; Adult; Azathioprine; Dermatomyositis; Evaluation Studies as Topic; Female; F | 1995 |
Strength in polymyositis and dermatomyositis: best outcome in patients treated early.
Topics: Biomechanical Phenomena; Creatine Kinase; Dermatomyositis; Female; Humans; Male; Middle Aged; Muscle | 1994 |
The effect of corticosteroids on inspiratory muscle performance in humans.
Topics: Adolescent; Adult; Female; Forced Expiratory Volume; Humans; Male; Muscle Contraction; Prednisone; R | 1993 |
Patients with chronic glucocorticoid treatment develop changes in muscle glycogen metabolism.
Topics: Adult; Aged; Alanine Transaminase; Aspartate Aminotransferases; Asthma; Creatine Kinase; Energy Meta | 1993 |
Polymyositis with plasma cell infiltrate in essential mixed cryoglobulinaemia.
Topics: Administration, Oral; Aged; Biopsy; Cryoglobulinemia; Diagnosis, Differential; Humans; Male; Muscle | 1993 |
Failure of pulse intravenous methylprednisolone treatment in juvenile dermatomyositis.
Topics: Administration, Oral; Anti-Inflammatory Agents; Child; Creatine Kinase; Dermatomyositis; Drug Admini | 1996 |
Dermatomyositis in association with tubulovillous adenoma: resolution after resection of adenoma.
Topics: Adenoma, Villous; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Biopsy; Cecal Neoplasms; Colono | 1997 |
Myasthenia in patients with dermatomyositis: clinical, electrophysiological and ultrastructural studies.
Topics: Adolescent; Adult; Biopsy; Dermatomyositis; Electromyography; Evoked Potentials; Fatigue; Female; Gl | 1978 |
Myasthenia gravis: pathogenesis, diagnosis, and therapy.
Topics: Adult; Autoimmune Diseases; Cholinesterase Inhibitors; Electromyography; Female; Humans; Infant, New | 1979 |
Prognostic value of minimal excitability of facial nerve in Bell's palsy.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Electric Stimulation; Evoked Potentials; Facial Mu | 1978 |
[Non-neoplastic Lambert-Eaton syndrome. A frequently missed diagnosis?].
Topics: Adult; Azathioprine; Diagnosis, Differential; Electric Stimulation; Female; Humans; Lambert-Eaton My | 1992 |
Serial evaluation of neuromuscular function in management of chronic inflammatory demyelinating polyneuropathy. A case report.
Topics: Activities of Daily Living; Adult; Chronic Disease; Combined Modality Therapy; Cyclophosphamide; Dem | 1987 |
Prednisone-induced worsening of neuromuscular function in myasthenia gravis.
Topics: Action Potentials; Adult; Aged; Female; Humans; Muscle Contraction; Myasthenia Gravis; Neuromuscular | 1986 |
Muscle morphology and enzymes in proximal and distal muscle groups of lower limb from patients with corticosteroid treated rheumatoid arthritis: the relationship to maximal isokinetic muscle strength.
Topics: 3-Hydroxyacyl CoA Dehydrogenases; Adult; Aged; Arthritis, Rheumatoid; Citrate (si)-Synthase; Female; | 1986 |
Isokinetic and isometric muscle strength in patients with rheumatoid arthritis. The relationship to clinical parameters and the influence of corticosteroid.
Topics: Adult; Aged; Arthritis, Rheumatoid; Female; Humans; Isometric Contraction; Middle Aged; Muscle Contr | 1986 |
The relationship between the leg muscle strength and physical capacity in patients with rheumatoid arthritis, with reference to the influence of corticosteroids.
Topics: Adult; Aged; Arthritis, Rheumatoid; Exercise Test; Female; Humans; Isometric Contraction; Middle Age | 1986 |
Thigh muscle mass and function in patients treated with glucocorticoids.
Topics: Adult; Exercise Therapy; Female; Humans; Kidney Transplantation; Male; Middle Aged; Muscle Contracti | 1985 |
Cortisone withdrawal rebound phenomena and histamine.
Topics: Asthma; Histamine; Histamine Release; Humans; Ileum; Muscle Contraction; Prednisone; Substance Withd | 1971 |
Adverse interaction between steroid hormones and anticholinesterase drugs.
Topics: Action Potentials; Animals; Anura; Cholinesterase Inhibitors; Dexamethasone; Drug Interactions; Edro | 1974 |
The diagnosis and management of myasthenia gravis.
Topics: Adrenocorticotropic Hormone; Edrophonium; Electric Stimulation; Evoked Potentials; Fingers; Humans; | 1974 |
Quadriceps femoris strength.
Topics: Adult; Age Factors; Aged; Arthritis, Rheumatoid; Biomechanical Phenomena; Electronics, Medical; Fati | 1973 |